 |
 |
||||||||||
 |
 |
|
|||||||||
 |
 |
 |
|
||||||||
 |
|
||||||||||
 |
|
||||||||||
 |
|
||||||||||
 |
|
||||||||||
 |
|
||||||||||
 |
 |
 |
 |
|
|||||||
|
OncoMed chooses SynCo Bio Partners to fill and finish its lead antibody GlaxoSmithKline And OncoMed Pharmaceuticals Form Strategic Alliance To Develop Cancer Stem Cell Antibody Therapeutics |
|
||||||||||
 |
OncoMed Pharmaceuticals is a biotechnology company dedicated to improving cancer treatment, by developing monoclonal antibodies that target the biologic pathways critical to tumor initiating cells, also known as “cancer stem cells”. We are leveraging our understanding of these tumor initiating cells to discover and develop novel therapeutics that could provide important alternatives for the treatment of cancer. |
 |
|
||||||||
 |
|
||||||||||
| Phenotypic characterization of human colorectal cancer stem cells. read more The prognostic role of a gene signature from tumorigenic breast-cancer cells. read more |
|
||||||||||
| OncoMed Pharmaceuticals, Inc. 800 Chesapeake Drive Redwood City, CA 94063 Copyright © 2007 |
 |
|
|||||||||
 |
Home | About Us | Research | Careers | News | Contact Us |
|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|